Diabetes (Type 2 ), taking METFORMIN
Merck is conducting a clinical research study for adults who are at least 25 years of age and have been diagnosed with type 2 diabetes. The purpose of this study is to compare the safety and effectiveness of the oral medications sitagliptin versus dapagliflozin for the treatment of type 2 diabetes as an add-on to metformin. The use of these medications combined with metformin is investigational.
Approximately 550 volunteers around the world will participate in this clinical research study.
The study medication will be provided to study participants at no charge. Nutrition and exercise counseling will also be provided.
The purpose of the study is to assess the effect of the addition of sitagliptin to metformin compared with the addition of dapagliflozin to metformin on hemoglobin A1c (A1C) over 24 weeks of treatment
7 VISITS TOTAL
ClinicalTrials.gov identifier: NCT02532855
ClinicalTrials.gov identifier: NCT02532855
| Condition | Diabetic Kidney Disease, NIDDM, Kidney Disease |
|---|---|
| Clinical Study Identifier | TX144229 |
| Sponsor | Merck |
| Last Modified on | 23 November 2020 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.